Jupiter Neurosciences, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christer Rosen
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1001 North US HWY 1 Jupiter FL United States of America 33477
- IPO Date
- Jan 18, 2022
- CIK
- 0001679628
- Website
- jupiterorphan.com
- Similar Companies
- Business
- Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical firm focused on the discovery and advancement of therapies for neuro-inflammation. The company leverages its proprietary JOTROL™ resveratrol platform, designed to deliver enhanced bioavailability and therapeutic levels without the typical gastrointestinal issues. Its robust pipeline includes several candidates undergoing development: JNS101 is progressing through Phase II trials for Friedreich's Ataxia, a rare inherited neurological disorder, and JNS102 is also in Phase II for Mucopolysaccharidosis Type I. Additionally, JNS107 is in Phase II for MELAS Syndrome, and JNS108 is in Phase II development for mild cognitive impairment and early Alzheimer's disease. Most recently, JOTROL™ received FDA IND clearance for its Phase 2a clinical trial in Parkinson's disease, with patient enrollment anticipated in early 2026. The company is also conducting early-stage development for JNS109 targeting amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 for COVID-19 treatment. Established in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., rebranded to Jupiter Neurosciences, Inc. in August 2021. Its headquarters are located in Jupiter, Florida. Beyond its pharmaceutical pipeline, the company is strategically expanding into the consumer longevity market with its Nugevia™ product line, set to launch in Q3 2025.
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit
Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Sees Significant Increase in Short Interest
Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14
Jupiter Neurosciences Investor News: Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation – JUNS
Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation – JUNS
Jupiter Neurosciences to Present at Emerging Growth Conference on April 2
Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago
Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference